Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

10X GENOMICS, INC.

(TXG)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
47.84 USD   -3.78%
02/02Singular Genomics' G4 Sequencing Platform Joins 10x Genomics Compatible Partner Program
MT
02/02UBS Initiates Coverage on 10x Genomics With Neutral Rating, $50 Price Target
MT
01/1910x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jumpcode Genomics Joins 10x Genomics' Compatible Partner Program (CPP)

12/01/2022 | 09:25am EST

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, today announced a partnership with 10x Genomics to integrate the Jumpcode Single Cell RNA Boost Kit with the 10x Genomics Chromium Single Cell Gene Expression platform.

Part of the Compatible Partner Program, the kit is verified with 10x Genomics' workflows.

We're honored to join the distinguished 10x Genomics Compatible Partner Program, which underscores the potential of leveraging our CRISPRclean technology to break barriers in research,' said Yaron Hakak, Ph.D., CEO of Jumpcode Genomics. 'Through this partnership, scientists using the 10x Genomics platform have the opportunity to significantly improve the sensitivity of single cell RNA sequencing and vastly increase the amount of usable data. By removing bias and simplifying workflows, together we're providing scientists with the ability to extract greater insights from cells.'

An abundance of uninformative sequences can obscure valuable next-gen sequencing (NGS) data. Jumpcode's CRISPRclean technology is changing that. Leveraging Cas9 and specifically designed guides, the Single Cell RNA Boost Kit degrades abundant, uninformative sequences in NGS libraries, redistributing 50% sequencing clusters to unique biologically relevant transcripts. Jumpcode's solution has now been validated with 10x Genomics' Chromium Single Cell 3' Gene Expression microfluidic platform which enables researchers to scale experiments for single cell analysis. The combination of these two technologies empowers scientists to cut through sequencing noise and boost usable data.

We are proud to welcome Jumpcode Genomics to the 10x Genomics Compatible Partner Program,' said Edwin Hauw, Vice President of Marketing for 10x Genomics. 'We share a belief that single cell analysis is key to accelerating research that can advance healthcare, and the combination of our platform with Jumpcode's kit will provide researchers with the novel technologies they need to uncover the next innovations in human health.'

About Jumpcode Genomics

Jumpcode Genomics is changing genomics with technology that allows scientists to break barriers limiting their research. Combining CRISPR-based technology and next-generation sequencing it's now possible to search for and find novel signals that were previously undetectable. Our technology removes uninformative sequences, allows researchers to extract greater insights, and broadens the understanding of human biology in fields from research to clinical applications. Discover what we can do at www.jumpcodegenomics.com.

About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. Our integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2021 based on publications and all of the top 20 global pharmaceutical companies by 2021 research and development spend and have been cited in over 4,100 research papers on discoveries ranging from oncology to immunology and neuroscience. Our patent portfolio comprises more than 1,600 issued patents and patent applications.

Contact:

Theresa Masnik

Email: jumpcodegenomics@shiftcomm.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about 10X GENOMICS, INC.
02/02Singular Genomics' G4 Sequencing Platform Joins 10x Genomics Compatible Partner Program
MT
02/02UBS Initiates Coverage on 10x Genomics With Neutral Rating, $50 Price Target
MT
01/1910x Genomics to Report Fourth Quarter and Full Year 2022 Financial Results on February ..
PR
01/09Transcript : 10x Genomics, Inc. Presents at 41st Annual J.P. Morgan Healthcar..
CI
01/05Cornell University : Method precisely locates gene activity and proteins across tissues
AQ
202210x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
2022Cancer researchers question antitrust arguments against Illumina-Grail deal
RE
2022Deutsche Bank Initiates Coverage on 10x Genomics With Buy Rating, $50 Price Target
MT
202210x Genomics : Investor Day Presentation
PU
202210x Genomics Commercially Launches Xenium Platform for In Situ Analysis
PR
More news
Analyst Recommendations on 10X GENOMICS, INC.
More recommendations
Financials (USD)
Sales 2022 508 M - -
Net income 2022 -184 M - -
Net cash 2022 211 M - -
P/E ratio 2022 -29,4x
Yield 2022 -
Capitalization 5 476 M 5 476 M -
EV / Sales 2022 10,4x
EV / Sales 2023 8,68x
Nbr of Employees 1 239
Free-Float 79,3%
Chart 10X GENOMICS, INC.
Duration : Period :
10x Genomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 10X GENOMICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 47,84 $
Average target price 49,70 $
Spread / Average Target 3,89%
EPS Revisions
Managers and Directors
Serge Saxonov Chief Executive Officer & Director
Benjamin J. Hindson Director
Justin J. McAnear Chief Financial & Accounting Officer
John R. Stuelpnagel Chairman
Michael Schnal-Levin Chief Technology Officer
Sector and Competitors